A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP

Inclusion criteria

• 1. Male or female participants ≥18 and ≤80 years of age

• have a diagnosis of HAP/VAP.

• have systemic signs and respiratory signs or symptoms of HAP/VAP.

• New or worsening infiltrate on chest X-ray/CT obtained within 48 hours prior to screening.

• The estimated survival time is at lest 28 days.

Exclusion criteria

• 1. Diagnosed or suspected CAP, Atypical pneumonias, Viral pneumonia or Chemical pneumonia.

• The total duration of antibiotic exposure for antibiotics whose administration begins in the 72 hours is longer than 24 hours.

• Acute Physiology and Chronic Health Evaluation (APACHE) II score >30.

• Allergic to any carbapenem, cephalosporin, penicillin, metronidazole disodium phosphate, other beta-lactam drugs or other beta-lactamase inhibitors and their auxiliary materials.

• Those who have a history of drug abuse or drug abuse within 6 months before screening.

• Those who participated in other clinical trials within 28 days before randomization and used any test drugs or medical devices.